Type 2 diabetes mellitus (T2DM) and obesity are both physiological conditions known as insulin resistance (IR), which is characterised by elevated blood insulin and glucose levels. In an animal model, inulin-type carbohydrate (ITC), a form of fermentable fructan, can lower blood sugar and improve insulin resistance, however there is debate over its potential benefits in human clinical studies. In order to assess the effectiveness of ITC supplementation in reducing IR in T2DM and obese patients, the authors carried out a comprehensive literature analysis. This involved supplementation with ITC in reducing IR in T2DM and obese patients. Studies using the meta-analysis of the following variables for T2DM patients were included: body mass index (BMI), fasting plasma glucose (FPG), fasting insulin (FI), HbA1c, homeostatic model assessment IR (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI). The main outcomes were determined to be HOMA-IR and QUICKI. A thorough analysis was done to determine how ITC affected IR in obese persons.